BBIO insider trading
HealthcareBridgeBio Pharma, Inc.: insider trade history from SEC Form 4 filings.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Company website: bridgebio.com
BBIO insider activity at a glance
FilingIQ tracks 763 insider transactions for BBIO in filings since Jun 28, 2019. The most recent transaction is dated Sep 17, 2026.
Across the full history, 25 open-market purchases
and 430 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on BBIO insider trades is 59.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest BBIO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading BBIO
13F funds holding BBIO
Frequently asked
- How many insider trades does FilingIQ track for BBIO?
- FilingIQ tracks 763 Form 4 insider transactions for BBIO (BridgeBio Pharma, Inc.), covering filings from Jun 28, 2019 onwards. 24 of those are dated within the last 90 days.
- Are BBIO insiders net buyers or net sellers?
- Across the full Form 4 history for BBIO, 25 transactions (3%) were open-market purchases and 430 (56%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BBIO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is BBIO in?
- BridgeBio Pharma, Inc. (BBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $14.53B.
Methodology & sources
Every BBIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.